Intravenous administration of piceatannol, an arginase inhibitor, improves endothelial dysfunction in aged mice
Intravenous administration of piceatannol, an arginase inhibitor, improves endothelial dysfunction in aged mice
- Minh Cong Nguyen Sungwoo Ryoo
- 대한생리학회-대한약리학회
- The Korean Journal of Physiology & Pharmacology
- 제21권 제1호
- 등재여부 : KCI등재
- 2017.01
- 83 - 90 (8 pages)
Advanced age is one of the risk factors for vascular diseases that are mainly caused by impaired nitric oxide (NO) production. It has been demonstrated that endothelial arginase constrains the activity of endothelial nitric oxide synthase (eNOS) and limits NO generation. Hence, arginase inhibition is suggested to be vasoprotective in aging. In this study, we examined the effects of intravenous injection of Piceatannol, an arginase inhibitor, on aged mice. Our results show that Piceatannol administration reduced the blood pressure in aged mice by inhibiting arginase activity, which was associated with NO production and reactive oxygen species generation. In addition, Piceatannol administration recovered Ca<sup>2+</sup>/ calmodulin-dependent protein kinase II phosphorylation, eNOS phosphorylation and eNOS dimer stability in the aged mice. The improved NO signaling was shown to be effective in attenuating the phenylephrine-dependent contractile response and in enhancing the acetylcholine-dependent vasorelaxation response in aortic rings from the aged mice. These data suggest Piceatannol as a potential treatment for vascular disease.